ReviewERJ open research2024
Digital markers of asthma exacerbations: a systematic review.
Review in ERJ open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- DELTA: Strengthening human biological resilience with an N=1 digital health and dynamic biomarker protocol.PloS one · 2026Trial
- Modeling Peak Expiratory Flow in Patients With Asthma and Quantifying Treatment Effects Using a Mixed-Effects Hidden Markov Model.CPT: pharmacometrics & systems pharmacology · 2026Article
- Biomarkers for selecting biologic therapies in asthma.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: With the increase in use of digital technologies, there is growing interest in digital markers, where technology is used to detect early markers of disease deterioration. The aim of this systematic review is to summarise the evidence relating to digital markers of asthma exacerbations. Methods: A systematic search of the following databases was conducted, using key search terms relating to asthma, digital and exacerbations: Ovid MEDLINE, EMBASE, Psycinfo, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials. Studies that aimed to explore the relationship between any digitally measured marker and asthma exacerbations using any form of portable digital sensor technology were included. Results: 23 papers were included. The digital markers related to five key categories: environmental, physiological, medication, lung function and breath-related parameters. The most commonly studied marker was lung function, which was reported in over half (13 out of 23) of the papers. However, studies were conflicting in terms of the use of lung function parameters as a predictor of asthma exacerbations. Medication parameters were measured in over a third of the studies (10 out of 23) with a focus on short-acting β-agonist (SABA) use as a marker of exacerbations. Only four and two studies measured heart rate and cough, respectively; however, both parameters were positively associated with exacerbations in all reported studies. Conclusion: Several digital markers are associated with asthma exacerbations. This suggests a potential role for using parameters such as heart rate, SABA use and, potentially, cough as digital markers of asthma exacerbations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.